From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or re ...

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City.Pfizer on Wednesday said it has launched a new multi-year program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition to another $4 billion cost-cutting effort, which Pfizer announced last year as demand for its Covid vaccine and oral drug Paxlovid slumped. In a securities filing, the pharmaceutical giant said the first phase of its new program is focused on ...

Pfizer stock lost nearly half its value over the past couple of years, but some of the world's most successful investors bought millions of shares in the first quarter.The past couple of years haven't been easy ones to be a Pfizer (PFE -0.38%) shareholder. The windfall profits its COVID-19 products produced in the early days of the pandemic evaporated much faster than expected.Disappointed investors have pushed Pfizer's stock price down by more than half from its peak in late 2021. Perhaps sensing a bargain ...

More than a dozen S&P 500 components sport "ultra-high yields." Two of these time-tested titans are begging to be bought by income seekers right now.Stocks have been a wealth-creating machine for investors over the long run. Though other asset classes have delivered a positive nominal return to patient investors, including gold, oil, housing, and Treasury bonds, none have come close to the annualized total return stocks have generated over the last century.While innovation is a key growth driver on Wall Str ...

Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.Are you famous enough for picking great stocks to become a billionaire money manager? If not, then there's a lot you could learn from the handful of folks who have.It's easier than ever for individuals to invest alongside the professionals. The U.S. Securities and Exchange Commission makes anyone with more than $100 million under management report their activity to the public every three months. T ...

JHVEPhoto Overview Pfizer (NYSE:PFE) (NEOE:PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a source of concern for many investors here as we try to figure out how PFE will whether that storm. I previously covered PFE back in January and rated it a Strong Buy, and the total return since then has been mostly flat. Data by YCharts I wanted to take this opportunity to ...

Investors might be remiss to overlook these stocks.The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You don't have to be rich to invest in the stock market.Whether you're new to investing or simply don't have a ton of extra cash on hand to put toward investing, you can still steadily build your portfolio through methods like dollar-cost averaging. If you have even $ ...

Simfo/E+ via Getty Images Pfizer (NYSE:PFE)(NEOE:PFE:CA) has been a losing investment idea for several years, really since peak pandemic demand was reached for its leading COVID vaccines and antiviral prescription drugs. I have mentioned the stock several times as a strong income/yield proposition starting in 2022, with better than sector average valuations. Yet, the share quote has responded with flat to even lower pricing. My last bullish article was posted in December here. Finally, some stronger tra ...

16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivot ...

Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25. However, recent developments suggest a potential turnaround for the pharmaceutical giant. On May 1, 2024, Pfizer reported better-than-expected results for the first quarter of the year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Their non-GAAP earnings per share of $0.82 surpassed expectations by $0.31, while revenue of $1 ...